Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
P07510
UPID:
ACHG_HUMAN
Alternative names:
-
Alternative UPACC:
P07510; B3KWM8; Q14DU4; Q53RG2
Background:
The Acetylcholine receptor subunit gamma plays a pivotal role in neuromuscular signaling, facilitating communication between nerve cells and muscles. This receptor is essential for muscle contraction, responding to the neurotransmitter acetylcholine by altering its conformation and opening an ion-conducting channel.
Therapeutic significance:
Mutations in the Acetylcholine receptor subunit gamma are linked to severe conditions such as Multiple pterygium syndrome, lethal type, and the Escobar variant. These genetic disorders manifest in multiple pterygia, arthrogryposis, and fetal akinesia, highlighting the protein's critical role in fetal development and neuromuscular function. Understanding the role of Acetylcholine receptor subunit gamma could open doors to potential therapeutic strategies.